ライフサイエンスコーパス: hyperimmune

1 h high viremia, suggesting a direct role for hyperimmune activation and an indirect role for viremia

2 , chronic IFN-I signaling is associated with hyperimmune activation and disease progression in persis

3 on of acutely SHIV-infected macaques induced hyperimmune activation and remarkable expansion of CD4+

4 type 1 (HIV-1) infection is associated with hyperimmune activation and systemic depletion of CD4(+)

5 e of chimpanzees to SIVcpz infection-induced hyperimmune activation could be the result of the expres

6 nation antiretroviral therapy by suppressing hyperimmune activation in HIV-infected individuals.

7 Hyperimmune activation is a strong predictor of disease

8 IL-15 has been implicated in the pathogenic hyperimmune activation that drives progressive HIV and S

9 nic SIV/HIV infections is marked by systemic hyperimmune activation, immune dysregulation, and profou

10 li strain SP16 (ATCC 49776) genomic DNA with hyperimmune and convalescent swine sera.

11 the native virus capsid and reacted with pig hyperimmune and convalescent-phase sera to PEC Cowden in

12 a coli cells, immunoblotted, and probed with hyperimmune and/or convalescent-phase antiserum to rapid

13 n guinea pigs were used to study the role of hyperimmune anti-glycoprotein B (gB) serum in modificati

14 alizing Abs cleared HIV faster compared with hyperimmune anti-HIV Ig (HIVIG), although the HIV Ab/Ag

15 Hyperimmune anti-HIV immunoglobulin (HIVIG) is derived f

16 The pharmacokinetics and safety of hyperimmune anti-human immunodeficiency virus (HIV) intr

17 In contrast, 2020 hyperimmune anti-severe acute respiratory syndrome coron

18 n antigen-detection ELISA was developed with hyperimmune antibodies raised to human group C rotavirus

19 production, high sensitivity to MmmSC rabbit hyperimmune antisera in vitro, and unique polymorphisms

20 ow the greatest sequence homology, we tested hyperimmune antisera prepared for each virus against bac

21 d SV capsid proteins were demonstrated using hyperimmune antisera raised in animals and sera collecte

22 n enzyme-linked immunosorbent assay based on hyperimmune antisera to recombinant SeV was highly speci

23 ed to identify epitopes recognized by rabbit hyperimmune antisera to Rickettsia prowazekii SPA.

24 an ex vivo borreliacidal assay to show that hyperimmune antiserum against DbpA, but not OspA, killed

25 with CT, and a reduced immunoreactivity with hyperimmune antiserum.

26 were randomly assigned (1:1:1) to take oral hyperimmune bIgG raised against CFA/I minor pilin subuni

27 in mouse colonization compared to commercial hyperimmune bovine colostrum product used for prevention

28 ve to the prophylactic use of antibiotics, a hyperimmune bovine milk antibody product with specific a

29 es and other novel biological agents such as hyperimmune caprine serum are being developed based on n

30 Oral administration of Imm124E hyperimmune colostrum ameliorated immune-mediated coliti

31 mmune modulatory effect of anti-LPS enriched hyperimmune colostrum, its ability to induce Tregs and a

32 Hyperimmune DbpA antiserum killed a large number of B. b

33 Plasma-derived polyclonal hyperimmune drugs have improved neutralization breadth c

34 gs were completely protected by injection of hyperimmune equine IgG when treatment was initiated earl

35 he profusion of new ideas for interventions, hyperimmune equine or ovine plasma-derived antivenoms re

36 ssigned to receive a monthly infusion of CMV hyperimmune globulin (at a dose of 100 mg per kilogram o

37 he neutralizing component of cytomegalovirus hyperimmune globulin (CMV-HIG), we performed serial depl

38 s followed by low-dose cytomegalovirus (CMV) hyperimmune globulin (CMV-Ig) combined with quadruple im

39 s that a combination of ganciclovir plus CMV hyperimmune globulin (CMVIG) is more effective than ganc

40 ere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe cor

41 Anti-cytomegalovirus (anti-CMV) hyperimmune globulin (HIG) has demonstrated efficacy in

42 Valacyclovir and CMV hyperimmune globulin (HIG) may reduce vertical transmiss

43 e of 2 doses (range, 1-6 doses) of high-dose hyperimmune globulin (HIG: 200 mg/kg/infusion).

44 erage of 2 doses (range 1 to 6) of high dose hyperimmune globulin (HIG: 200 mg/kg/infusion).

45 ized to receive either 100 mg/kg intravenous hyperimmune globulin (IVIG), derived from donors immuniz

46 ared aggressive CMV prophylaxis (n = 21, CMV hyperimmune globulin [CMVIG] plus four weeks of intraven

47 the usefulness of bridge therapies, such as hyperimmune globulin and convalescent human plasma, and

48 203 women (22.7%) in the group that received hyperimmune globulin and of 37 of 191 women (19.4%) in t

49 s reactive with gM/gN from pooled human HCMV hyperimmune globulin by affinity purification using reco

50 women who could be evaluated, treatment with hyperimmune globulin did not significantly modify the co

51 % (18 fetuses or infants of 61 women) in the hyperimmune globulin group and 44% (27 fetuses or infant

52 curred in 4.9% of fetuses or neonates in the hyperimmune globulin group and in 2.6% in the placebo gr

53 One participant in the hyperimmune globulin group had a severe allergic reactio

54 obstetrical adverse events was higher in the hyperimmune globulin group than in the placebo group (13

55 Participants who received hyperimmune globulin had a higher incidence of headaches

56 unity as achieved in the passive transfer of hyperimmune globulin has had a tremendous impact on publ

57 We evaluated the efficacy of hyperimmune globulin in a phase 2, randomized, placebo-c

58 lactic vaccine or for producing C. difficile hyperimmune globulin is justified.

59 ere acute respiratory syndrome coronavirus 2 hyperimmune globulin may be a valuable treatment in seve

60 Monoclonal antibodies and hyperimmune globulin may provide additional preventive s

61 r the presumed onset of infection to receive hyperimmune globulin or placebo every 4 weeks until 36 w

62 Immunoprophylaxis with hyperimmune globulin or with a humanized monoclonal anti

63 Each hyperimmune globulin product comprised thousands to tens

64 Among pregnant women, administration of CMV hyperimmune globulin starting before 24 weeks' gestation

65 shed in 2005, administration of CMV-specific hyperimmune globulin to pregnant women with primary CMV

66 ntreated congenital infection, HCMV-specific hyperimmune globulin treatment, and uninfected controls.

67 With hyperimmune globulin treatment, placentas appeared uninf

68 ent plasma (CCP), monoclonal antibodies, and hyperimmune globulin, are among the leading treatments f

69 76% of neutralizing activities in HCMV human hyperimmune globulin, consistent with earlier reports th

70 maximum of six treatments, plus intravenous hyperimmune globulin, tacrolimus, mycophenolate mofetil,

71 uality attributes comparable to those of CMV hyperimmune globulin.

72 high-risk (D+/R-) for CMV also received CMV hyperimmune globulin.

73 oNT/A, a potency 90 times greater than human hyperimmune globulin.

74 erience gained can be applied to manufacture hyperimmune globulins against other emerging viruses.

75 tibody-dependent enhancement of disease, and hyperimmune globulins specific for lung pathogens presen

76 SARS-CoV-2) in under 3 months, Fc-engineered hyperimmune globulins specific for Zika virus that lacke

77 Using this approach, we generated hyperimmune globulins with potent neutralizing activity

78 epertoires to create recombinant multivalent hyperimmune globulins.

79 m patients with active coccidioidomycosis, a hyperimmune goat anti-Ag2 serum, and a murine anti-Ag2 m

80 genes of bovine rotavirus strain UK, and two hyperimmune guinea pig antisera to each reassortant, and

81 enom antibodies from the memory B cells of a hyperimmune human donor with extensive snake venom expos

82 These findings could explain the efficacy of hyperimmune IgG for treatment of primary CMV infection d

83 piratory syndrome coronavirus 2 (SARS-CoV-2) hyperimmune immunoglobulin (hIG) from human convalescent

84 ined with human immunodeficiency virus (HIV) hyperimmune immunoglobulin (HIVIG) infusions administere

85 of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin (HIVIG) were assessed in 30 H

86 nistration of convalescent plasma, serum, or hyperimmune immunoglobulin may be of clinical benefit fo

87 transfusion or by being used to manufacture hyperimmune immunoglobulin preparations.

88 d that convalescent plasma or anti-influenza hyperimmune intravenous immunoglobulin (hIVIG) might hav

89 ) antibody responses to anti-influenza virus hyperimmune intravenous immunoglobulin (hIVIG) were char

90 py using infusion of convalescent plasma (or hyperimmune intravenous immunoglobulin) has been reporte

91 thy volunteers for the purpose of developing hyperimmune intravenous immunoglobulin.

92 Hyperimmune, late xenograft rejection, and naive sera we

93 -specific affinity-purified IgG from malaria hyperimmune Liberian adults, was assessed by the opsonic

94 N40 and 9 B. afzelii PKo isolates from OspC hyperimmune mice or among 10 B. burgdorferi s.s. N40 and

95 N40 and 10 B. afzelii PKo isolates from DbpA hyperimmune mice, compared with input inocula.

96 library by probing with anti-E. chaffeensis hyperimmune mouse ascitic fluid.

97 Using hyperimmune mouse sera against each of 11 Chlamydia spp.

98 V) virus and rMuVJL5 were demonstrated using hyperimmune mouse serum samples and a curated panel of h

99 ree ORFs, only M83 is strongly recognized by hyperimmune mouse serum.

100 ed infusions of immunoglobulins, either with hyperimmune or standard preparations, may help to reduce

101 at is dependent on monocytic cells, but this hyperimmune phenotype and its protective effects are los

102 ns were observed by CCIF between TGEV Miller hyperimmune pig antisera and all PEDV strains.

103 In this study, hyperimmune plasma from sheep immunised with whole spike

104 Two whole-IgG formulations were prepared via hyperimmune plasma precipitation with caprylic acid and

105 R. equi pneumonia in foals is transfusion of hyperimmune plasma, which is expensive and carries the r

106 reatment of serious influenza is infusion of hyperimmune plasma.

107 n (CT), and enhanced immunoreactivity with a hyperimmune polyclonal antiserum generated against whole

108 sted the efficacy of convalescent plasma IgG hyperimmune product (ZIKV-IG) isolated from individuals

109 help guide selection of convalescent plasma, hyperimmune products, monoclonal antibodies, and vaccine

110 hamsters that were passively immunized with hyperimmune rabbit anti-rAceES-2 serum exhibited more ra

111 A hyperimmune rabbit antiserum to an E2 hypervariable regi

112 er previous intravenous exposure of mice and hyperimmune rabbit serum did not neutralize the activity

113 feri B31 genomic library with cross-adsorbed hyperimmune rabbit serum.

114 brane proteins as determined by probing with hyperimmune rabbit serum.

115 broadest antibody response was obtained for hyperimmune rabbits with WR, which is pathogenic in rabb

116 y therapeutic anti-SARS-CoV-2 immunoglobulin hyperimmune (rCIG).

117 erate potential antagonists of these serious hyperimmune reactions, we engineered soluble TCR mutants

118 f gut microbiota drives a state of dysbiotic hyperimmune response at secondary lymphoid tissues drain

119 ring B lymphocytes typical of a Th2-mediated hyperimmune response.

120 haracterized by an uncontrolled, persistent, hyperimmune response.

121 e therapeutically useful for attenuating the hyperimmune responses in a number of disorders.

122 bitory subunit (Galphai2) induces Th1-skewed hyperimmune responses in the colon, leading to chronic c

123 provide important clues regarding GC-related hyperimmune responses in the context of disease progress

124 1 is a potential therapeutic target to block hyperimmune responses induced by gram-negative bacteria.

125 odel have implications for understanding the hyperimmune responses that characterize some human disea

126 rise to adults with fewer Wigglesworthia and hyperimmune responses.

127 counting for the observed colonic Th1-skewed hyperimmune responses.

128 Injection of the hyperimmune sera (IgG) into normoglycemic nude mice bear

129 Hyperimmune sera from 40 of 47 patients showed an anti-a

130 Mouse hyperimmune sera generated against TBE serocomplex virus

131 The hyperimmune sera induced by the combined conjugates exhi

132 hibition and neutralization assays that used hyperimmune sera obtained from caesarian-derived, colost

133 ated neutralization titers exceeding that of hyperimmune sera of rabbits immunized with PA in Freund'

134 Passive transfer of either P. y. yoelii hyperimmune sera or anti-GST-PYC2 sera directed to the m

135 and simultaneous transfer of tumor cells and hyperimmune sera protected naive animals against tumor g

136 onally, passive transfer studies with rabbit hyperimmune sera raised against the J5 vaccine revealed

137 Hyperimmune sera raised against virus-like particles (VL

138 Hyperimmune sera raised against virus-like particles (VL

139 was completely inhibited by the addition of hyperimmune sera raised to the major fimbriae.

140 etions on both termini with bovine anti-PlpE hyperimmune sera showed that the immunodominant region i

141 fe preventive and therapeutic substitute for hyperimmune sera to treat tetanus in mice.

142 Titration curves of hyperimmune sera were included on assay plates, assay si

143 were high, similar to those of pooled human hyperimmune sera.

144 Infusion of Lewis rat-specific hyperimmune serum (0.2 ml) resulted in HAR of Lewis rat

145 The majority of animals receiving hyperimmune serum after virus exposure and during early

146 We examined the effect of hyperimmune serum and primed T cells on the survival of

147 Hyperimmune serum and sensitized splenocytes were prepar

148 Both hyperimmune serum and the mAb reacted with intact human

149 stablished islet xenografts are resistant to hyperimmune serum as a result of a lack of target endoth

150 heart grafts were rejected after transfer of hyperimmune serum but not late xenograft rejection serum

151 Transfer of hyperimmune serum containing anti-C6VL TCR Abs into na i

152 well as by immunoblot analysis with a rabbit hyperimmune serum directed against a gH synthetic peptid

153 Hyperimmune serum from vaccinated mice reacted specifica

154 In contrast, SIV hyperimmune serum given subcutaneously prior to oral SIV

155 All animals administered hyperimmune serum homologous to the challenge virus befo

156 Reports of the use of hyperimmune serum in human influenza infection are spora

157 successful intervention by administration of hyperimmune serum may be narrow.

158 Performed before infection, transfer of hyperimmune serum prolonged survival of C3aR(-/-) mice.

159 Because passive transfer of hyperimmune serum protected mice from HSV-1 infection, w

160 of HCV in vitro was attempted with a rabbit hyperimmune serum raised against a homologous synthetic

161 e N-specific monoclonal antibody and various hyperimmune serum samples from ruminants.

162 Similarly, mice passively immunized with hyperimmune serum showed an inhibited B-cell response up

163 orcine islets removed from mice treated with hyperimmune serum showed no staining for IgG.

164 - and postexposure passive immunization with hyperimmune serum to prevent oral simian immunodeficienc

165 mouse serum, we investigated the ability of hyperimmune serum to recombinant Osp C (N40) to protect

166 Although use of hyperimmune serum to treat patients with severe influenz

167 protection was not completely restored after hyperimmune serum transfer.

168 Hyperimmune serum was administered 24 hrs before virus e

169 When this SIV hyperimmune serum was given to 3 newborns 3 weeks after

170 e toxins or toxoids) or passively immunized (hyperimmune serum) against combinations of superantigens

171 ice treated with normal human serum (NHS) or hyperimmune serum, or into presensitized GT-Ko mice.

172 arental viruses when tested against parental hyperimmune serum.

173 ci than did those from recipients of anti-gB hyperimmune serum.

174 on on the pharmacokinetics and efficacy of a hyperimmune severe acute respiratory syndrome coronaviru

175 ation activities comparable to the best from hyperimmune sources.

176 memory circuitry and performance and with a hyperimmune state, 50 years later.

177 from immune-mediated destruction in clinical hyperimmune syndromes.